Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.
Data pager
Data pager
Posts per page:
PageSizeComboBox
select
6 page(s)
Sort order
Data pager
Data pager
Posts per page:
PageSizeComboBox
select
6 page(s)
 July 1, 2026   Sweden

In an interview with BioStock, Diamyd Medical’s Head of Manufacturing Site, Sofia Mayans, discusses the search for a strategic partner for the company’s newly GMP-certified manufacturing facility in Umeå.

– It is about finding our niche. We are trying to read the market, understand what is needed, and talk to potential partners to see whether we could fit into their operations, says Sofia Mayans.

Read the article here

 June 25, 2026   Sweden
”Times are really tough currently. Whilst I do not wish anybody to go through what we currently are experiencing, I feel the need to step in as the CEO. At least for a short while. Yes, I am an old man. But with some experience.” So writes Anders Essen-Möller in his CEO statement in Diamyd Medical’s Q3 report. It is an unusually candid letter from a founder stepping back in at the helm of a company he built, at a moment when it stands at a crossroads.

Read the article here
 June 5, 2026   Sweden
Diamyd Medical reports that it has received several external proposals, including Letters of Intent and invitations to invest in various projects, as part of its ongoing strategic review. Following the discontinuation of the Phase III DIAGNODE-3 trial, the company is implementing cost-saving measures and evaluating strategic alternatives under the leadership of founder and CEO Anders Essen-Möller.

Read the article here
 May 26, 2026   Sweden
Umeå Biotech Incubator highlights Diamyd Medical’s GMP approval for its Umeå facility, noting its strategic importance for life science, regional preparedness and future pharmaceutical manufacturing. In the interview, Sofia Mayans, Head of Manufacturing Site Umeå, describes the approval as a major strength for the region.

Read the full article here
 May 21, 2026   Sweden
In an interview with BioStock, Sofia Mayans, Head of Manufacturing, comments on the GMP certification from the Swedish Medical Products Agency. The certification marks an important milestone for Diamyd Medical’s recombinant protein platform and strengthens the company’s position for future manufacturing, partnerships, and expansion opportunities.

Read the article here

Order GAD for preclinical research

GAD PRODUCTS